Abstract

This study was designed to investigate the effects of Sangrovit on performance, small intestinal morphology, and immune response of 300 commercial hybrid broilers, Ross 308. The study was conducted in the Agricultural Research Station of Islamic Azad University, Varamin, in the spring 2010 for 42 days. The broilers were kept in a completely randomized design with 3 treatments, 4 replicates, 12 experimental units each containing 25 broilers. Treatments used in this experiment included controls, 0.05 % and 0.1 % Sangrovit of total ration. The test results showed no significant difference between different treatments during the breeding period on feed intake, feed conversion, and small intestinal morphology. However, treatments containing 0.1% Sangrovit showed significant differences on weight gain in the early rounds between the other treatments (P<0.05). Statistically, these differences were not significant during the breeding period. Regarding the effects of different treatments on the carcass components, the diet containing 0.05% Sangrovit could significantly increase the weight of the thigh (P<0.05) than the other diets. In this treatment, the mean serum antibody titers against Newcastle disease by HI method showed significant differences at 35 and 42 days of the breeding period (P<0.05). Based on the results of this experiment, Sangrovit can obtain the desired results in improving immune system, performance and carcass yield.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.